Update on Edoxaban for the prevention and treatment of thromboembolism: Clinical applications based on current evidence

Advances in Hematology

Volumn 2015, Issue , 2015, Pages

  Zalpour, Ali ^a   Oo, Thein Hlaing ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; EDOXABAN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ATRIAL FIBRILLATION; BLEEDING; BRAIN ISCHEMIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CEREBROVASCULAR ACCIDENT; DRUG MECHANISM; HEMOSTASIS; HIP FRACTURE; HIP SURGERY; HUMAN; KIDNEY DYSFUNCTION; KNEE SURGERY; LIVER DYSFUNCTION; PATIENT EDUCATION; PATIENT SATISFACTION; PERIOPERATIVE PERIOD; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; THROMBOSIS PREVENTION;

EID: 84940764141     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2015/920361     Document Type: Review

References (98)

1. D. Wardrop and D. Keeling, "The story of the discovery of heparin and warfarin," British Journal of Haematology, vol. 141, no. 6, pp. 757-763, 2008.
2. J. Hirsh, M. ODonnell, and J. W. Eikelboom, "Beyond unfractionated heparin and warfarin: current and future advances," Circulation, vol. 116, no. 5, pp. 552-560, 2007.
3. J. vanRyn, A. Goss, N. Hauel et al., "The discovery of dabigatran etexilate," Frontiers in Pharmacology, vol. 4, article 12, Article ID Article 12, 2013.
4. P. C. Wong, D. J. P. Pinto, and D. Zhang, "Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor," Journal of Thrombosis and Thrombolysis, vol. 31, no. 4, pp. 478-492, 2011.
5. E. Perzborn, S. Roehrig, A. Straub, D. Kubitza, and F. Misselwitz, The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor," Nature Reviews Drug Discovery, vol. 10, no. 1, pp. 61-75, 2011.
6. C. H. Yeh, J. C. Fredenburgh, and J. I. Weitz, "Oral direct factor Xa inhibitors," Circulation Research, vol. 111, no. 8, pp. 1069-1078, 2012.
7. L. Loffredo, L. Perri, M. Del Ben, F. Angelico, and F. Violi, New oral anticoagulants for the treatment of acute venous thromboembolism: are they safer than vitamin K antagonists? A meta-analysis of the interventional trials," Internal and Emergency Medicine, 2014.
8. A. Zalpour and T. H. Oo, "Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence," Journal of Drug Design, Development and Therapy, vol. 8, pp. 2181-2191, 2014.
9. D. M. Monroe, "Basic principles underlying coagulation," in Practical Hemostasis and Thrombosis, N. Key, M. Makris, D. OShaughnessy, and D. Lillicrapt, Eds., pp. 1-6, Wiley-Blackwell, Oxford, UK, 2nd edition, 2009.
10. D. Gailani and T. Renné, "Intrinsic pathway of coagulation and arterial thrombosis," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 12, pp. 2507-2513, 2007.
11. N. Mackman, R. E. Tilley, and N. S. Key, "Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 8, pp. 1687-1693, 2007.
12. V. Toschi and M. Lettino, "Inhibitors of propagation of coagulation: factors V and X," British Journal of Clinical Pharmacology, vol. 72, no. 4, pp. 563-580, 2011.
13. F. Scaglione, "Neworal anticoagulants: comparative pharmacology with vitamin K antagonists," Clinical Pharmacokinetics, vol. 52, no. 2, pp. 69-82, 2013.
14. J. Hirsh and M. N. Levine, "Low molecular weight heparins," Blood, vol. 79, no. 1, pp. 1-17, 1992.
15. K. G. Mann, K. Brummel, and S. Butenas, "What is all that thrombin for?" Journal of Thrombosis and Haemostasis, vol. 1, no. 7, pp. 1504-1514, 2003.
16. G. Escolar, M. Diaz-Ricart, E. Arellano-Rodrigo, and A. M. Galán, "The pharmacokinetics of edoxaban for the prevention and treatment of venous thromboembolism," Expert Opinion on Drug Metabolism and Toxicology, vol. 10, no. 3, pp. 445-458, 2014.
17. Edoxaban Prescribing Information, 2015, http://www.accessdata.fda.gov/drugsatfdadocs/label/2015/206316lbl.pdf.
18. K. Ogata, J. Mendell-Harary, M. Tachibana et al., "Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers," Journal of Clinical Pharmacology, vol. 50, no. 7, pp. 743-753, 2010.
19. M. S. Bathala, H. Masumoto, T. Oguma, L. He, C. Lowrie, and J. Mendell, "Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor xa inhibitor, in humans," Drug Metabolism & Disposition, vol. 40, no. 12, pp. 2250-2255, 2012.
20. H. Bounameaux and A. J. Camm, "Edoxaban: an update on the new oral direct factor Xa inhibitor," Drugs, vol. 74, no. 11, pp. 1209-1231, 2014.
21. O. Q. P. Yin and R. Miller, "Population pharmacokinetics and dose-exposure proportionality of edoxaban in healthy volunteers," Clinical Drug Investigation, vol. 34, no. 10, pp. 743-752, 2014.
22. J. D. Wessler, L. T. Grip, J. Mendell, and R. P. Giugliano, "The P-glycoprotein transport system and cardiovascular drugs," Journal of theAmericanCollege of Cardiology, vol. 61, no. 25, pp. 2495-2502, 2013.
23. T. Mikkaichi, Y. Yoshigae, H. Masumoto et al., "Edoxaban transport via P-glycoprotein is a key factor for the drugs disposition," Drug Metabolism and Disposition, vol. 42, no. 4, pp. 520-528, 2014.
24. O. Yousuf and D. L. Bhatt, "The evolution of antiplatelet therapy in cardiovascular disease," Nature Reviews Cardiology, vol. 8, no. 10, pp. 547-559, 2011.
25. J. Yeung and M. Holinstat, "Newer agents in antiplatelet therapy: a review," Journal of Blood Medicine, vol. 3, pp. 33-42, 2012.
26. E. Nutescu, I. Chuatrisorn, and E. Hellenbart, "Drug and dietary interactions of warfarin and novel oral anticoagulants: an update," Journal of Thrombosis and Thrombolysis, vol. 31, no. 3, pp. 326-343, 2011.
27. J. Mendell, F. Lee, S. Chen, V. Worland , M. Shi, and M. M. Samama, "The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor xa inhibitor," Journal of Cardiovascular Pharmacology, vol. 62, no. 2, pp. 212-221, 2013.
28. J. D. Wessler, L. T. Grip, J. Mendell, and R. P. Giugliano, "The P-glycoprotein transport system and cardiovascular drugs," Journal of the American College of Cardiology, vol. 61, no. 25, pp. 2495-2502, 2013.
29. April 2015, https://www.clinicalpharmacology.com.
30. J. D. Douketis, A. C. Spyropoulos, F. A. Spencer et al., "Perioperative management of antithrombotic therapy. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines," Chest, vol. 141, no. 2, supplement, pp. e326S-e350S, 2012.
31. A. C. Spyropoulos and J. D. Douketis, "How I treat anticoagulated patients undergoing an elective procedure or surgery," Blood, vol. 120, no. 15, pp. 2954-2962, 2012.
32. T. Fuji, C.-J. Wang, S. Fujita et al., "Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial," Thrombosis Research, vol. 134, no. 6, pp. 1198-1204, 2014.
33. G. Raskob, A. T. Cohen, B. I. Eriksson et al., "Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement," Thrombosis and Haemostasis, vol. 104, no. 3, pp. 642-649, 2010.
34. S. Rohatagi, J. Mendell, H. Kastrissios et al., "Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery," Thrombosis and Haemostasis, vol. 108, no. 5, pp. 887-895, 2012.
35. T. Fuji, S. Fujita, S. Tachibana et al., "Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V trial," in Proceedings of the 52nd Annual Meeting of the American Society of Hematology, p. 3320, Orlando, Fla, USA, December 2010.
36. T. Fuji, S. Fujita, Y. Kawai et al., "Safety and efficacy of edoxaban in patients undergoing hip fracture surgery," Thrombosis Research, vol. 133, no. 6, pp. 1016-1022, 2014.
37. The Hokusai-VTE Investigators, "Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism," The New England Journal of Medicine, vol. 369, pp. 1406-1415, 2013.
38. R. P. Giugliano, C. T. Ruff, E. Braunwald et al., "Edoxaban versus warfarin in patients with atrial fibrillation," The New England Journal of Medicine, vol. 369, no. 22, pp. 2093-2104, 2013.
39. R. N. H. Pugh, I. M. Murray-Lyon, and J. L. Dawson, "Transection of the oesophagus for bleeding oesophageal varices," British Journal of Surgery, vol. 60, no. 8, pp. 646-649, 1973.
40. J. Graff and S. Harder, "Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment," Clinical Pharmacokinetics, vol. 52, no. 4, pp. 243-254, 2013.
41. W. E. Dager and T. H. Kiser, "Systemic anticoagulation considerations in chronic kidney disease," Advances in Chronic Kidney Disease, vol. 17, no. 5, pp. 420-427, 2010.
42. H. Heidbuchel, P. Verhamme, M. Alings et al., "European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation," Europace, vol. 15, no. 5, pp. 625-651, 2013.
43. Y. Koretsune, T. Yamashita, and M. Yasaka, "Evaluation of edoxaban in patients with atrial fibrillation and severe renal impairment," European Heart Journal, vol. 34, supplement 1, 2013.
44. D. A. Parasrampuria, T. Marbury, N. Matsushima et al., "Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis," Thrombosis and Haemostasis, vol. 113, no. 4, pp. 719-727, 2015.
45. P. B. Nielsen, D. A. Lane, L. H. Rasmussen, G. Y. H. Lip, and T. B. Larsen, "Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and metaregression analysis," Clinical Research in Cardiology, vol. 104, no. 5, pp. 418-429, 2015.
46. T. Fuji, S. Fujita, Y. Kawai et al., "A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery," Thrombosis Journal, vol. 13, article 6, 2015.
47. H. Kawaji, M. Ishii, Y. Tamaki, K. Sasaki, and M. Takagi, Edoxaban for prevention of venous thromboembolism after major orthopedic surgery," Orthopedic Research and Reviews, vol. 4, pp. 53-64, 2012.
48. P. Kinov, P. P. Tanchev, M. Ellis, and G. Volpin, "Antithrombotic prophylaxis in major orthopaedic surgery: an historical overview and update of current recommendations," International Orthopaedics, vol. 38, no. 1, pp. 169-175, 2014.
49. Y. Falck-Ytter, C. W. Francis, N. A. Johanson et al., "Prevention ofVTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines," Chest, vol. 141, supplement 2, pp. e278S-e325S, 2012.
50. T. Fuji, S. Fujita, S. Tachibana, and Y. Kawai, "A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolismin patients undergoing total knee arthroplasty," Journal of Thrombosis and Haemostasis, vol. 8, no. 11, pp. 2458-2468, 2010.
51. H. Sasaki, K. Ishida, N. Shibanuma et al., "Retrospective comparison of three thromboprophylaxis agents, edoxaban, fondaparinux, and enoxaparin, for preventing venous thromboembolism in total knee arthroplasty," International Orthopaedics, vol. 38, no. 3, pp. 525-529, 2014.
52. T. Fuji, C. J. Wang, S. Fujita, Y. Kawai, T. Kimura, and S. Tachibana, "Safety and efficacy of edoxaban, an oral factor Xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan," The Journal of Arthroplasty, vol. 29, no. 12, pp. 2439-2436, 2014.
53. A. C. Spyropoulos, F. A. Anderson Jr., G. FitzGerald et al., Predictive and associative models to identify hospitalized medical patients at risk for VTE," Chest, vol. 140, no. 3, pp. 706-714, 2011.
54. M. M. Samama, A. T. Cohen, J.-Y. Darmon et al., "A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients," The New England Journal of Medicine, vol. 341, no. 11, pp. 793-800, 1999.
55. A. Leizorovicz, A. T. Cohen, A. G. G. Turpie, C.-G. Olsson, P. T. Vaitkus, and S. Z. Goldhaber, "Randomized, placebocontrolled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients," Circulation, vol. 110, no. 7, pp. 874-879, 2004.
56. A. T. Cohen, B. L. Davidson, A. S. Gallus et al., "Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acutemedical patients: randomised placebo controlled trial," British Medical Journal, vol. 332, no. 7537, pp. 325-329, 2006.
57. V. F. Tapson, H. Decousus, M. Pini et al., "Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the international medical prevention registry on venous thromboembolism," Chest, vol. 132, no. 3, pp. 936-945, 2007.
58. C. Kearon, E. A. Akl, A. J. Comerota et al., "Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines," Chest, vol. 141, supplement 2, pp. e419S-e494S, 2012.
59. S. Z. Goldhaber, A. Leizorovicz, A. K. Kakkar et al., "Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients," The New England Journal of Medicine, vol. 365, no. 23, pp. 2167-2177, 2011.
60. A. T. Cohen, T. E. Spiro, H. R. Buller et al., "Rivaroxaban for thromboprophylaxis in acutely ill medical patients," The New England Journal of Medicine, vol. 368, pp. 513-523, 2013.
61. M. G. Beckman, W. C. Hooper, S. E. Critchley, and T. L. Ortel, Venous thromboembolism a public health concern," American Journal of Preventive Medicine, vol. 38, no. 4, pp. S495-S501, 2010.
62. C. Kearon, E. A. Akl, A. J. Comerota et al., "Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines," Chest, vol. 141, no. 2, supplement, pp. e419S-e494S, 2012.
63. R. Bauersachs, S. D. Berkowitz, B. Brenner et al., "Oral rivaroxaban for symptomatic venous thromboembolism," The New England Journal of Medicine, vol. 363, no. 26, pp. 2499-2510, 2010.
64. H. R. Büller, M. Prins, A. W. A. Lensing et al., "Oral rivaroxaban for the treatment of symptomatic pulmonary embolism," The New England Journal of Medicine, vol. 366, no. 14, pp. 1287-1297, 2012.
65. G. Agnelli, H. R. Buller, A. Cohen et al., "Oral apixaban for the treatment of acute venous thromboembolism," The New England Journal of Medicine, vol. 369, no. 9, pp. 799-808, 2013.
66. P. Prandoni, F. Noventa, A. Ghirarduzzi et al., "The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1, 626 patients," Haematologica, vol. 92, no. 2, pp. 199-205, 2007.
67. M. Carrier, G. Le Gal, P. S. Wells, and M. A. Rodger, "Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism," Annals of Internal Medicine, vol. 152, no. 9, pp. 578-589, 2010.
68. G. Agnelli, H. R. Buller, A. Cohen et al., "Apixaban for extended treatment of venous thromboembolism," The New England Journal of Medicine, vol. 368, no. 8, pp. 699-708, 2013.
69. R. Bauersachs, S. D. Berkowitz, B. Brenner et al., "Oral rivaroxaban for symptomatic venous thromboembolism," The New England Journal of Medicine, vol. 363, pp. 2499-2510, 2010.
70. A. Varki, "Trousseaus syndrome: multiple definitions and multiplemechanisms," Blood, vol. 110, no. 6, pp. 1723-1729, 2007.
71. T. Wun and R. H. White, "Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors," Cancer Investigation, vol. 27, no. 1, pp. 63-74, 2009.
72. C. E. Chee, A. A. Ashrani, R. S. Marks et al., "Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study," Blood, vol. 123, no. 25, pp. 3972-3978, 2014.
73. J. Trujillo-Santos, J. A. Nieto, G. Tiberio et al., "Predicting recurrences or major bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry," Thrombosis & Haemostasis, vol. 100, no. 3, pp. 435-439, 2008.
74. A. Khorana, N. M. Kuderer, E. Culakova, G. H. Lyman, and C. W. Francis, "Development and validation of a predictive model for chemotherapy-associated thrombosis," Blood, vol. 111, no. 10, pp. 4902-4907, 2008.
75. M. N. Levine, C. Gu, H. A. Liebman et al., "A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer," Journal of Thrombosis and Haemostasis, vol. 10, no. 5, pp. 807-814, 2012.
76. M. H. Prins, A. W. A. Lensing, T. A. Brighton et al., "Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials," The Lancet Haematology, vol. 1, no. 1, pp. e37-e46, 2014.
77. T. B. Larsen, P. B. Nielsen, F. Skøjoth et al., "Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a systemic review and meta-analysis of safety and efficacy outcomes," PLoS ONE, vol. 9, no. 12, Article ID e114445, 2014.
78. M. C. Vedovati, F. Germini, G. Agnelli, and C. Becattini, "Direct oral anticoagulants in patients With VTE and cancer," Chest Journal, vol. 147, no. 2, pp. 475-483, 2015.
79. NCCN, April 2015, http://www.nccn.org/professionals/physiciangls/pdf/vte.pdf.
80. G. H. Lyman, K. Bohlke, A. A. Khorana et al., "Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update 2014," Journal of Clinical Oncology, vol. 33, no. 6, pp. 654-656, 2015.
81. J. L. Mega, E. Braunwald, S. D. Wiviott et al., "Rivaroxaban in patients with a recent acute coronary syndrome," The New England Journal of Medicine, vol. 366, no. 1, pp. 9-19, 2012.
82. J. H. Alexander, R. D. Lopes, S. James et al., "Apixaban with antiplatelet therapy after acute coronary syndrome," The New England Journal of Medicine, vol. 365, no. 8, pp. 699-708, 2011.
83. E. C. Jauch, J. L. Saver, H. P. Adams et al., "Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals fromthe AmericanHeart Association/American Stroke Association," Stroke, vol. 44, no. 3, pp. 870-947, 2013.
84. M. U. Zafar, D. A. Vorchheimer, J. Gaztanaga et al., "Antithrombotic effects of factor Xa inhibitionwithDU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber," Thrombosis and Haemostasis, vol. 98, no. 4, pp. 883-888, 2007.
85. J. I. Weitz, S. J. Connolly, I. Patel et al., "Randomised, parallelgroup, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation," Thrombosis and Haemostasis, vol. 104, no. 3, pp. 633-641, 2010.
86. Y. Morishima and C. Kamisato, "Laboratory measurements of the oral direct factor xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay," The American Journal of Clinical Pathology, vol. 143, no. 2, pp. 241-247, 2015.
87. T. Fukuda, Y. Honda, C. Kamisato, Y. Morishima, and T. Shibano, "Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents," Thrombosis and Haemostasis, vol. 107, no. 2, pp. 253-259, 2012.
88. E. Herzog, F. Kaspereit, W. Krege et al., "Effective reversal of edoxaban-associated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage," Anesthesiology, vol. 122, no. 2, pp. 387-398, 2015.
89. A.-B. Halim, M. M. Samama, and J. Mendell, "Ex vivo reversal of the anticoagulant effects of edoxaban," Thrombosis Research, vol. 134, no. 4, pp. 909-913, 2014.
90. S. Kaatz, P. A. Kouides, D. A. Garcia et al., "Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors," American Journal of Hematology, vol. 87, no. 1, pp. S141-S145, 2012.
91. L. M. Baumann Kreuziger, J. C. Keenan, C. Morton, and D. J. Dries, "Management of bleeding patient receiving new oral anticoagulants: a role for thrombin complex concentrates," BioMed Research International, vol. 2014, Article ID 583794, 7 pages, 2014.
92. H. Zahir, K. S. Brown, A. G. Vandell et al., "Edoxaban effects on bleeding following punch biopsy and reversal by a 4-FPCC prothrombin complex concentrate," Circulation, vol. 131, pp. 82-90, 2015.
93. Y. Mo and F. K. Yam, "Recent advances in the development of specific antidotes for target-specific oral anticoagulants," Pharmacotherapy, vol. 35, no. 2, pp. 198-207, 2015.
94. J. W. Eikelboom, M. Brueckmann, F. van de Werf et al., Dabigatran versus warfarin in patients with mechanical heart valves," The New England Journal of Medicine, vol. 369, no. 13, pp. 1206-1214, 2013.
95. M. H. Prins, L. Bamber, S. J. Cano et al., "Patient-reported treatment satisfaction with oral rivaroxaban versus stand ard therapy in the treatment of pulmonary embolism: results from the EINSTEIN-PE trial," Thrombosis Research, vol. 135, no. 2, pp. 281-288, 2015.
96. L. Bamber, M. Y. Wang, M. H. Prins et al., "Patient-reported treatment satisfaction with oral rivaroxaban versus stand ard therapy in the treatment of acute symptomatic deep-vein thrombosis," Thrombosis and Haemostasis, vol. 110, no. 4, pp. 732-741, 2013.
97. M. Mahmoudi and D. M. Sobieraj, "The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecularweight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery," Pharmacotherapy, vol. 33, no. 12, pp. 1333-1340, 2013.
98. A. Amin, A. Bruno, J. Trocio, J. Lin, and M. Lingohr-Smith, Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with nonvalvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US," Journal of Medical Economics, vol. 18, no. 6, pp. 399-409, 2015.